Charles Schwab
SPRB

Charles Schwab’s Spruce Biosciences SPRB Stock Holding History

Charles Schwab’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-204
Closed -$7.92K – 3619
2024
Q2 		$7.92K Hold
204
– – ﹤0.01% 3620
2024
Q1 		$12K Hold
204
– – ﹤0.01% 3456
2023
Q4 		$44.8K Hold
204
– – ﹤0.01% 3414
2023
Q3 		$34.6K Hold
204
– – ﹤0.01% 3445
2023
Q2 		$32.9K Buy
+204
New +$34.1K ﹤0.01% 3487
2022
Q2 		– Sell
-246
Closed -$38K – 3664
2022
Q1 		$38K Hold
246
– – ﹤0.01% 3558
2021
Q4 		$83K Hold
246
– – ﹤0.01% 3459
2021
Q3 		$111K Sell
246
-330
-57% -$207K ﹤0.01% 3370
2021
Q2 		$485K Sell
576
-13
-2% -$13.9K ﹤0.01% 3176
2021
Q1 		$733K Buy
589
+51
+9% +$78.3K ﹤0.01% 2950
2020
Q4 		$981K Buy
+538
New +$892K ﹤0.01% 2782

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's SPRB Position: Q3 2024 in Review

Charles Schwab sold out of Spruce Biosciences (SPRB) in Q3 2024, closing a stake of 204 shares — an estimated $7.92K sold.

Charles Schwab first reported a position in SPRB in Q4 2020 and held it in 11 quarters. The position peaked at $981K in Q4 2020. 29 funds tracked by Wall St. Rank hold SPRB as of Q3 2024.

  • Charles Schwab reported no remaining Spruce Biosciences position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 204 Spruce Biosciences shares in Q3 2024, an estimated $7.92K.
  • Charles Schwab first reported a position in Spruce Biosciences in Q4 2020 and held it in 11 quarters.
  • Charles Schwab's Spruce Biosciences position peaked at $981K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.